Biopharma AI
By
Is Merck’s WINREVAIR Set to Redefine First-Year PAH Treatment? Phase 3 HYPERION Results Show Over 70% Clinical Event Risk Reduction in Newly Diagnosed Patients
Key Takeaways:• Game-Changing Efficacy: WINREVAIR™ (sotatercept-csrk) cut clinical worsening risk in PAH by a statistically significant margin in…
Can Sanofi’s Sarclisa-VRd Regimen, Backed by EMA’s CHMP, Redefine Frontline Standards in Transplant-Eligible Multiple Myeloma?
Key Highlights EMA’s CHMP Endorses Sarclisa-VRd for Frontline Multiple Myeloma in Transplant-Eligible AdultsOn June 23, 2025, Sanofi announced…
Could Lilly’s Oral GLP-1 Orforglipron Revolutionize Type 2 Diabetes Treatment? Complete Phase 3 Results Show Compelling Efficacy and Safety on Par with Injectable GLP-1 Therapies
Key Highlights Orforglipron Delivers Clinically Meaningful Glycemic and Weight ImprovementsThe ACHIEVE-1 Phase 3 trial established orforglipron’s efficacy, showing…
How Caris Life Sciences’ $7.6B IPO the Breakout Moment for AI-Powered TechBio in Oncology and Beyond?
Key Highlights AI Meets Molecular Medicine: A New TechBio Contender EmergesCaris Life Sciences’ successful IPO positions it as…
Can Google DeepMind’s Isomorphic Labs Revolutionize Clinical Trials with AI-Designed Drugs Backed by $600M and AlphaFold Breakthrough?
Key Takeaways AI to Clinic: Isomorphic Labs Moves Beyond Design to Human TrialsIsomorphic Labs, the AI drug discovery…
Five Breakthrough AI Innovations Set to Transform Healthcare in 2025
The healthcare industry is poised for a major transformation in 2025 as artificial intelligence (AI) technologies continue to…
